Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature (Q35028863)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

5 August 2017

0 references

Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature (English)

1 reference

Europe PubMed Central

5 August 2017

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

Giuseppe Nunnari

4

object named as

Giuseppe Nunnari

1 reference

Europe PubMed Central

5 August 2017

Bruno Cacopardo

1

object named as

Bruno Cacopardo

1 reference

Europe PubMed Central

5 August 2017

Marilia Rita Pinzone

3

object named as

Marilia Rita Pinzone

1 reference

Europe PubMed Central

5 August 2017

author name string

Francesco Benanti

2

1 reference

Europe PubMed Central

5 August 2017

publication date

30 October 2013

1 reference

Europe PubMed Central

5 August 2017

BMC Research Notes

1 reference

Europe PubMed Central

5 August 2017

6

1 reference

Europe PubMed Central

5 August 2017

437

1 reference

Europe PubMed Central

5 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

30 October 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

https://scigraph.springernature.com/pub.10.1186/1756-0500-6-437

0 references

The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Microbial translocation in chronic liver diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Hepatocellular carcinoma in HIV-infected patients: check early, treat hard

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Current practice of hepatitis C treatment in Southern Italy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Hepatitis C and interferon induced thyroiditis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Potential mechanisms of interferon-alpha induced autoimmunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Side effects of therapy of hepatitis C and their management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Natural history of hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

8 July 2018

Rheumatoid arthritis following a treatment with IFN-alpha/ribavirin against HCV infection.

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-6-437

21 January 2018

Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-α2a treatment for chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-6-437

21 January 2018

Leukocyte interferon alpha early retreatment for Child A HCV genotype 1b-infected cirrhotics intolerant to pegylated interferons

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-6-437

21 January 2018

Hepatitis C virus-related skin diseases

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-6-437

21 January 2018

Prolonged treatment with interferon alpha and peginterferon induces rheumatoid arthritis syndrome and erythema nodosum.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

25 October 2018

Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

25 October 2018

Rheumatoid arthritis probably induced by pegylated interferon in a patient with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815306

25 October 2018

Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24171974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leucocyte interferon-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons

1 reference

https://pubmed.ncbi.nlm.nih.gov/24171974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1756-0500-6-437

1 reference

Europe PubMed Central

5 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35028863&oldid=2004213585"